Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC

H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Related Videos
Expert on NSCLC
Related Content